NYSE:PMTobacco
Does FDA’s ZYN Ruling And Mixed Q2 Results Change The Bull Case For Philip Morris (PM)?
In the past week, Philip Morris International reported second‑quarter 2026 results showing sales rising to US$11.19 billion from US$10.14 billion a year earlier, while net income eased to US$2.82 billion and diluted EPS from continuing operations slipped to US$1.80 from US$1.95.
A key development was the U.S. FDA’s authorization of ZYN nicotine pouches as modified risk tobacco products, making ZYN the first nicotine pouch brand with this status and highlighting the growing regulatory...